Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Non-Current Liabilities (2021 - 2025)

Rxo (RXO) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $698.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 5.29% year-over-year to $698.0 million, compared with a TTM value of $698.0 million through Dec 2025, down 5.29%, and an annual FY2025 reading of $698.0 million, down 5.29% over the prior year.
  • Total Non-Current Liabilities was $698.0 million for Q4 2025 at Rxo, down from $714.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $793.0 million in Q3 2024 and bottomed at $182.0 million in Q4 2021.
  • Average Total Non-Current Liabilities over 5 years is $597.7 million, with a median of $624.0 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 241.21% in 2022, then decreased 11.59% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $182.0 million in 2021, then surged by 241.21% to $621.0 million in 2022, then fell by 11.59% to $549.0 million in 2023, then soared by 34.24% to $737.0 million in 2024, then fell by 5.29% to $698.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for RXO at $698.0 million in Q4 2025, $714.0 million in Q3 2025, and $733.0 million in Q2 2025.